reports
Autolus Therapeutics to Report Second Quarter 2025 Financial Results a...
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BS...
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Hoste
- Michiel Declercq
Autolus Aucatzyl gains EC approval in r/r adult ALL
Autolus announced that the European Commission (EC) has granted marketing authorization for Aucatzyl (obe-cel, CD19 CAR-T) for the treatment of adults aged 26+ years with r/r B-ALL. Autolus will now evaluate market entry opportunities in the EU, which we expect to take place on a country-by-country basis – the company has previously indicated that the initial focus in the EU will be on Germany. More broadly, the US commercial launch in r/r adult ALL began in early 2025, and the first quarter of ...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therape...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
Hyloris Positive bioavailability study results for Atomoxetine Oral So...
Hyloris announced positive results from a pivotal clinical bioavailability study of its proprietary Atomoxetine Oral Solution, which demonstrated comparable relative bioavailability under fasted conditions to Strattera (atomoxetine) capsules. Following the study results, Hyloris can move ahead with regulatory submission to the FDA in the US. We expect Hyloris to find a partner for US commercialisation, and model peak royalty revenue of € 19m for Atomoxetine Oral Solution in the US. We reiterate ...
- Luis de Toledo Heras
SCR SCOR SE
SCMN SWISSCOM AG
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
EZJ EASYJET PLC
RY4C RYANAIR HOLDINGS PLC
SIX2 SIXT SE
DLG DE'LONGHI S.P.A.
ONTEX ONTEX GROUP N.V.
ENG ENAGAS SA
FLU FLUGHAFEN WIEN AG
MOB MOBILEZONE HOLDING AG
VOS VOSSLOH AG
NSI NSI N.V.
BAR BARCO NV
AF AIR FRANCE - KLM
R3NK RENK GROUP AG
SUNN SUNRISE
- Luis de Toledo Heras
SCR SCOR SE
SCMN SWISSCOM AG
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
EZJ EASYJET PLC
RY4C RYANAIR HOLDINGS PLC
SIX2 SIXT SE
DLG DE'LONGHI S.P.A.
ONTEX ONTEX GROUP N.V.
ENG ENAGAS SA
FLU FLUGHAFEN WIEN AG
MOB MOBILEZONE HOLDING AG
VOS VOSSLOH AG
NSI NSI N.V.
BAR BARCO NV
AF AIR FRANCE - KLM
R3NK RENK GROUP AG
SUNN SUNRISE
- Stefano Toffano
- ING Helpdesk
Benelux Morning Notes
Ahold Delhaize: Peer Albertsons 1Q25/26 results ASML: 2Q25 results; good update, focus on FY26 Barco: 1H25 results; margin uplift despite headwinds Belgian Telecoms: DIGI fixed internet launch in Wallonia Flow Traders: June global volume rises but volatility declines MoM NSI: Good operational results, cautious outlook Ontex: Sizeable profit warning calls for material consensus downgrade
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock opti...
- ING Helpdesk
Benelux Morning Notes
Aalberts: Acquisition of Asian semiconductor player. ASML: Preview 2Q25; building backlog for 2026. BAM: 1H25 preview - YoY improvement from UK. Barco: Preview 1H25F; significant headwinds. Econocom: Acquires four specialist AV companies under ‘One Econocom' strategic plan. Flow Traders: Preview 2Q25. Staffing: Page Group 2Q25 trading update; soft 2Q25 especially in perm; outlook in line. WDP: €41m sale-and-lease back in France
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Ekopak appoints Jean-Baptiste De Cuyper as new CEO Ekopak (EKOP:xbru), a company specialized in circular water solutions, announces the appointment of Jean-Baptiste De Cuyper as its new CEO. This appointment follows the earlier communication of May 12, 2025, in which the company announced its intention to appoint an external candidate for this key role. The appointment is part of Ekopak's broader efforts to strengthen its governance and management structure. Jean-Baptiste De Cuyper brings more than twenty years of international experience in the water, energy, and infrastructure sectors, t...
Ekopak benoemt Jean-Baptiste De Cuyper als nieuwe CEO
Ekopak benoemt Jean-Baptiste De Cuyper als nieuwe CEO Ekopak (EKOP:xbru), een onderneming gespecialiseerd in circulaire wateroplossingen, kondigt de benoeming aan van Jean-Baptiste De Cuyper als nieuwe CEO. Deze aanstelling volgt op de eerdere communicatie van 12 mei 2025 waarin het bedrijf haar intentie bekendmaakte om een externe kandidaat aan te stellen voor deze sleutelrol. De benoeming past binnen Ekopak’s bredere inspanningen om haar governance en managementstructuur te versterken. Jean-Baptiste De Cuyper brengt meer dan twintig jaar internationale ervaring met zich mee in de sectore...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
Hyloris Agreement with Kuvatris could generate a priority review vouch...
Hyloris announced the signing of an R&D funding agreement of $ 2m (plus $ 1.6m equity investment) with Kuvatris to support the development and US approval of intravenous (IV) suramin to treat human African trypanosomiasis (HAT). Given the rare nature of HAT, the value of this program lies in its potential to secure a transferable PRV. Recent examples show PRVs being sold for $160m – Hyloris could get just over 50% of net proceeds, if successful. We see this as a creative deal to boost the compan...
- Guy Sips
Barco Beam Me Up, Barco – But Not Too Fast
Is Barco's strategy beginning to bear fruit, or is one swallow not making a summer? We are happy we gave them the benefit of the doubt after the FY24 results and 1Q25 trading update, given the structural improvements made over the past few years that have continued into the first months of 2025. Recently, we saw some multiple expansion in our SOTP-valuation. This combined with rolling forward our DCF, results in a higher TP of € 14.0 (was € 13.4). However, despite Barco not updating its guidanc...
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Thomas Vranken
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.